These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7553634)

  • 1. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
    Borghaei H; Alpaugh RK; Bernardo P; Palazzo IE; Dutcher JP; Venkatraj U; Wood WC; Goldstein L; Weiner LM
    J Immunother; 2007; 30(4):455-67. PubMed ID: 17457220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
    Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
    Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
    Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
    Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
    Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
    J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Deo Y; Graziano R; Fisher JL; Meyer L; Mrozek-Orlowski M
    J Clin Oncol; 1995 Sep; 13(9):2281-92. PubMed ID: 7545221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
    Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
    Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with CD64-directed immunotherapy. An overview.
    Curnow RT
    Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
    Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
    Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
    Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.